Novo Nordisk A/S
CSE:NOVO B
Net Margin
Novo Nordisk A/S
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.6T DKK |
36%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
673.8B USD |
26%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
-4%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
431.3B USD |
25%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
208B CHF |
14%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
185.6B GBP |
15%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
197.4B CHF |
25%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
219.8B USD |
26%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
183.4B USD |
-126%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
147.1B USD |
17%
|
|
| FR |
|
Sanofi SA
PAR:SAN
|
109.5B EUR |
21%
|
Novo Nordisk A/S
Glance View
In the heart of Denmark, Novo Nordisk A/S stands as a beacon of innovation in the pharmaceutical industry, tracing its roots back to the early 20th century when it began as a small insulin-producing laboratory. This company, now a global heavyweight, is renowned for its dedication to diabetes care, a commitment that has driven its meteoric rise. Novo Nordisk's operations are deeply entrenched in the discovery, development, and production of medicines aimed at treating chronic diseases such as diabetes, obesity, and rare blood and endocrine disorders. Their prowess in biotechnology is not only evident in their diverse product portfolio but also in their relentless pursuit of new therapeutics through cutting-edge research and development, underscoring their mantra of improving the quality of life for millions across the globe. At its core, Novo Nordisk's business model is a sophisticated blend of patient-centric innovation and strategic market outreach. Sales of insulin and GLP-1 receptor agonists form the backbone of their revenue, targeting a growing global demographic faced with diabetes and related metabolic conditions. Their manufacturing process is a finely-tuned system that transforms complex scientific discoveries into tangible, effective treatments. Through strategic pricing, partnerships, and expansion in both mature and emerging markets, Novo Nordisk skillfully maneuvers the intricate web of global healthcare demands. By leveraging a robust pipeline of new drugs and improving access to existing therapies, the company not only secures its financial health but also ensures that its impact on healthcare remains profound and far-reaching.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Novo Nordisk A/S's most recent financial statements, the company has Net Margin of 35.6%.
You don't have any saved screeners yet